VitaDAO 💛 (@vitadao) / X

VitaDAO 💛

8,544 posts

VitaDAO 💛

@vitadao

VitaDAO is a community owned collective funding early stage longevity research,governed by $VITA-holders 🧬 👉discord.gg/vitadao

Ethereum

Joined February 2021

Pinned
VitaDAO 💛
@vitadao
Apr 7
Our March longevity newsletter is here. • Rubedo's GPX4 modulator hits positive Phase 1 results in psoriasis and atopic dermatitis • Cyclarity publishes landmark 7KC review, Phase 1 readout coming later this year • Eli Lilly signs deal worth up to $2.75B with Insilico
6K
VitaDAO 💛
@vitadao
Jun 10
The VitaDAO May Longevity Newsletter is live. This month: - Cyclarity reports first Phase 1 data — UDP-003 drove dose-dependent 7KC excretion in humans - Repair Biotechnologies received FDA RDEP eligibility for REP-0003 in HoFH - The NAD debate continues, with a new paper and a
The VitaDAO Longevity Newsletter May ’26 | VitaDAO
From vitadao.com
154K
VitaDAO 💛
@vitadao
Jun 3
NewLimit is going after aging as a root driver by restoring cell function. Their prototype is now heading into the clinic next year. Good to see this approach moving forward. 🫡
Brian Armstrong
@brian_armstrong
Jun 2
Aging is arguably the root cause of most major diseases (loss of function in our cells). Four years ago, we made a bet that aging was treatable, and NewLimit was born. NewLimit now has a prototype drug that reverses the age of some human cells (restores function they had when
2.4K
VitaDAO 💛
@vitadao
Jun 2
.@Cyclarity , backed by @vitadao, presented Phase 1 results for UDP-003 at AHA Vascular Discovery. First human evidence that 7-ketocholesterol (7KC), a driver of arterial plaque, can be safely excreted. All endpoints met, no SAEs. Phase 2 on plaque regression in 2026.
globenewswire.com
Cyclarity Unveils First-Ever Clinical Data Demonstrating Excretion of Oxidized Cholesterol, at...
Safe excretion of 7KC, a core driver of plaque associated with heart disease, stroke, inflammation, and age-related diseases, in humans suggests medicine...
1.1K
VitaDAO 💛 reposted
Michael Torres
@Mykalt45
May 25
Looking forward to attending. Will have an @artan_bio off-site as well. We’re cooking, fam!
Molecule
@Molecule_sci
May 18
Our flagship conference @DeSciBerlin is just one month away. Hosted in a brutalist church attached to an art gallery, it'll be our fifth year convening to discuss what the world looks like at the intersection of science and technology. Join us!
2.3K
VitaDAO 💛 reposted
Anthony Schwartz, PhD
@aschwartzphd
May 20
I'm looking forward to presenting @artan_bio's longevity pipeline and our decentralized model, which has helped us accelerate our work faster than traditional funding modalities. Longevity Day at @NFCsummit, Lisbon; June 4th, 2026. @vitarnabio @vitadao #Desci #longevity
2.6K
VitaDAO 💛 reposted
Avi Roy
@agingroy
May 15
Atherosclerosis kills 20 million people a year. Statins slow plaque growth. Nothing approved today reverses it. Cyclarity just reported the first human evidence that oxidized cholesterol can be selectively removed from the body. Their drug, UDP-003, is an engineered
VitaDAO 💛
@vitadao
May 15
Cyclarity Phase 1 of UDP-003 met all endpoints. First clinical evidence that humans can safely excrete 7-ketocholesterol, a root driver of atherosclerosis. Dose-dependent urinary excretion, no SAEs, ~3hr half-life. Phase 2 (plaque regression endpoint) planned later in 2026.
36K
VitaDAO 💛 reposted
Aubrey de Grey
@aubreydegrey
May 15
The first case of a SENS spinout getting this far! Massive congrats to Oki and his team.
VitaDAO 💛
@vitadao
May 15
Cyclarity Phase 1 of UDP-003 met all endpoints. First clinical evidence that humans can safely excrete 7-ketocholesterol, a root driver of atherosclerosis. Dose-dependent urinary excretion, no SAEs, ~3hr half-life. Phase 2 (plaque regression endpoint) planned later in 2026.
17K
VitaDAO 💛
@vitadao
May 15
Cyclarity Phase 1 of UDP-003 met all endpoints. First clinical evidence that humans can safely excrete 7-ketocholesterol, a root driver of atherosclerosis. Dose-dependent urinary excretion, no SAEs, ~3hr half-life. Phase 2 (plaque regression endpoint) planned later in 2026.
globenewswire.com
Cyclarity Unveils First-Ever Clinical Data Demonstrating Excretion of Oxidized Cholesterol, at...
Safe excretion of 7KC, a core driver of plaque associated with heart disease, stroke, inflammation, and age-related diseases, in humans suggests medicine...
83K
VitaDAO 💛 reposted
Michael Torres
@Mykalt45
May 14
Thanks @bradloncar for highlighting my work! I do think there’s interesting concepts in the DeSci space. Doing my part to shed light into it. @vitarnabio @vitadao @Molecule_sci @artan_bio
BiotechTV
@BiotechTV
May 14
𝐀𝐒𝐆𝐂𝐓 𝟐𝟎𝟐𝟔: @Mykalt45 isn't slowing down after selling his antibody-drug conjugate company to Eli Lilly. Here's his gene therapy play. Full video: biotechtv.com/post/asgct-202…
00:00
11M
VitaDAO 💛 reposted
Michael Torres
@Mykalt45
May 5
Another VitaBeauty Update. In this experiment we were testing a few different sequences to rescue p53 in cells with an arginine nonsense mutation in p53, a well known tumor suppressor. You see a nice dose response between 5 ug and 10 ug. This is the Artan-102 (last lane) science
140K
VitaDAO 💛
@vitadao
May 4
RT @a_miloski: Been a long building season at @vitadao. a few updates: 1/ VitaApp is in private alpha. selected community members being se…
483
VitaDAO 💛 reposted
Michael Torres
@Mykalt45
May 4
Shows up translated to me, but awesome write up on what I’m bringing to the DeSci space. I work hard to create value for everyone around me and importantly, I make sure everyone wins as best I can. @vitarnabio @artan_bio $vitarna
0xWangXK🔶BNB
@0xWangXKK
May 4
@BioProtocol + @vitadao 科学家 Michael Torres @Mykalt45 创立的 CrossBridge Bio，已被 Eli Lilly（礼来）以最高 3亿美元收购，这笔交易让 Michael Torres 成为“从大学授权到被全球最大药企收购”的典型成功案例。以下是BIO,VitaDao,CrossBridge Bio及Michael Torres之间的关系： 1.
5.7K